Dyslipideamia
Drug research and approvals for dyslipideamia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 0 studies of dyslipideamia are recruiting on ClinicalTrials.gov, and Health Canada has authorized 7 drug trials for it since 2013.
- Recruiting worldwide: 0
- Trials authorized in Canada: 7
- FDA orphan approvals: 0
- EU medicines: 0
Newest first; search them all in Canada trials
| Aug 12, 2022 | A phase 2 open-label extension study to evaluate the long-term safety and efficacy of aro-APOC3 in adults with dyslipidemiaPlozasiran (ARO-APOC3) | Arrowhead Pharmaceuticals, Inc. | Closed |
| May 4, 2021 | A double-blind, placebo-controlled phase 2b study to evaluate the efficacy and safety of ARO-ANG3 in adults with mixed dyslipidemiaZodasiran (ARO-ANG3, ADS-004) | Arrowhead Pharmaceuticals, Inc. | Closed |
| Aug 20, 2020 | A phase 2b randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to assess the efficacy, safety, and tolerability of vupanorsen…Vupanorsen (PF-07285557, isis 703802) | Pfizer | Closed |
| Oct 8, 2014 | A phase-3, double-blind, double-dummy, randomized, placebo and active controlled, parallel-group study to assess the efficacy, safety, and tolerability of…RN316 (PF-04950615) | Pfizer | Ongoing |
| May 16, 2014 | A phase 3 double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of PF-04950615 in subjects with…RN316 (PF-04950615) | Pfizer | Ongoing |
| Mar 28, 2014 | A double-blind, randomized, placebo-controlled, multicenter study to evaluate safety and efficacy of evolocumab (amg 145) in combination with statin therapy in…Evolocumab (amg 145) | Amgen | Ongoing |
| Oct 2, 2013 | Effects of selective inhibition of cholesterol absorption with ezetimibe on intestinal cholesterol homeostasis in dyslipidemic men with insulin-resistance - a…Ezetimibe | Dr. Patrick Couture | Pending |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA